Anzeige
Mehr »
Freitag, 30.01.2026 - Börsentäglich über 12.000 News
Goldaktie mit Turbo: 9 von 13 Treffern in den ersten 25 Metern!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PQ7G | ISIN: SE0012853455 | Ticker-Symbol: 6EQ
Tradegate
29.01.26 | 21:04
32,670 Euro
-0,27 % -0,090
1-Jahres-Chart
EQT AB Chart 1 Jahr
5-Tage-Chart
EQT AB 5-Tage-Chart
RealtimeGeldBriefZeit
32,58032,69008:07
32,57032,68008:07

Aktuelle News zur EQT AB Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiEQT Foundation opens applications for breakthrough science grants to reduce dependence on critical minerals for the green transition312EQT Foundation opens applications for deeptech solutions grants, tackling critical mineral dependence in climate technologiesThe program will award between EUR 25,000 and EUR 100,000STOCKHOLM...
► Artikel lesen
MoEinstieg ins Secondaries-Geschäft: EQT erwirbt Coller Capital7
23.01.EQT kauft Secondaries-Gigant Coller Capital für 3,2 Milliarden Dollar6
23.01.Sweden's EQT Leans Into Secondaries Story, Agrees Coller Capital Bid2
22.01.Coller Capital To Become Part Of EQT's Global Platform3
22.01.Sweden's EQT to buy secondaries firm Coller Capital for up to $3.7bn5
22.01.EQT To Acquire Coller Capital In $3.2 Billion Share Deal, Launching New Secondaries Segment2
22.01.EQT to acquire Coller Capital in deal valued at up to $3.7bn3
EQT AB Aktie jetzt für 0€ handeln
22.01.EQT strikes $3.2bn deal for Coller Capital to enter secondaries market6
22.01.EQT AB Non-GAAP EPS of €1.12, revenue of €2.73B3
22.01.EQT To Buy Coller Capital For Initial $3.2 Bln356LONDON (dpa-AFX) - EQT AB (EQT.ST, EQBBF), a Swedish investment company, said on Thursday that it has inked a deal to acquire Coller Capital, a British private equity company, for a base consideration...
► Artikel lesen
22.01.EQT AB (publ) Year-end Report 20253352025 - A year of strong executionSTOCKHOLM, Jan. 22, 2026 /PRNewswire/ -- "2025 was a year of great progress and strong execution for EQT. We navigated a volatile market environment, achieved...
► Artikel lesen
22.01.EQT AB FY25 Net Income Down On Weak Revenues; EBITDA, Margin Rise; To Buy Coller Capital297STOCKHOLM (dpa-AFX) - EQT AB (EQT.ST), a Swedish investment company, reported Thursday that its fiscal 2025 net profit declined from last year with weak revenues. However, EBITDA, a key earnings...
► Artikel lesen
22.01.EQT AB Reports Decline In H2 Bottom Line228STOCKHOLM (dpa-AFX) - EQT AB (EQT.ST) reported earnings for second half that Drops, from last yearThe company's bottom line came in at EUR382 million, or EUR0.325 per share. This compares with...
► Artikel lesen
22.01.EQT to combine with Coller Capital to enter secondaries, marking the next step in EQT's strategic evolution578EQT to acquire Coller Capital, a leading global secondaries firm with nearly USD 50 billion in total assets under management1 across institutional, private wealth and insurance-related capitalThe...
► Artikel lesen
21.01.EQT plans venture continuation fund as secondaries expand3
20.01.EQT Life Sciences Co-leads 51 Mln EUR Funding Of Exciva's Deraphan For Alzheimer's Disease345STOCKHOLM (dpa-AFX) - EQT AB (EQBBF,EQT.ST), an equity and venture capital firm under the life sciences category, announced that its LSP Dementia Fund has co-led a 51 million euros Series B...
► Artikel lesen
20.01.EQT Life Sciences co-leads €51 million funding for Alzheimer's therapy9
20.01.Alzheimer-Therapie: Exciva sichert sich 51 Millionen Euro unter Führung von EQT Life Sciences4
20.01.EQT Life Sciences co-leads EUR 51 million Series B in Exciva to advance its Alzheimer's therapy into clinical Phase 2167Series B financing will support Exciva's Phase 2 clinical trial of its lead candidate, Deraphan, for agitation associated with Alzheimer's disease (AD)Financing was co-led by EQT Life Sciences...
► Artikel lesen
Weiter >>
300 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2